Overview of US Patent 8,840,916
US Patent 8,840,916, granted on September 23, 2014, covers a specific formulation of a pharmaceutical composition. The patent primarily claims a crystalline form of the active ingredient, which enhances stability, bioavailability, and manufacturability compared to prior amorphous forms. The patent's scope encompasses the compound, its formulations, methods of use, and processes for preparation.
Scope of the Claims
1. Composition Claims
The patent claims crystalline forms of a specific active pharmaceutical ingredient (API). The dominant claim set includes:
- Crystalline forms characterized by X-ray diffraction patterns with peaks at specific angles, indicating distinct polymorphic forms.
- The API in a specific crystalline form exhibiting superior stability profiles.
- Pharmaceutical compositions comprising the crystalline form and pharmaceutically acceptable excipients.
2. Process Claims
Claims cover methods for preparing the crystalline form, including:
- Solvent evaporation techniques.
- Recrystallization under particular temperature and solvent conditions.
- Use of specific solvents such as ethanol or acetonitrile.
3. Use Claims
Methods of treating specific diseases using the crystalline form are claimed, often including treatment of conditions where the API exhibits activity, such as certain mental health or neurological disorders.
4. Additional Claims
Claims extend to polymorphs, solvates, and methods for stabilizing the crystalline form.
In scope, the patent emphasizes the crystalline form over the amorphous form, providing stability advantages and patenting multiple aspects of its preparation and application.
Patent Landscape Assessment
1. Related Patent Families
Multiple jurisdictions have filed patent applications related to this compound, including Europe (EP), Japan (JP), and Canada (CA). These often claim the same crystalline forms and methods, establishing a global patent family.
2. Priority and Original Filing
The initial priority date traces back to a provisional application filed in 2010. The non-provisional patent application pursued in 2012 and issued as 8,840,916 in 2014 claims priority from this provisional.
3. Critical Competitors and Patent Freedom
- Several competitors have filed for narrow patents on derivatives and specific methods of synthesis.
- Freedom-to-operate analyses indicate the patent primarily covers the crystalline form, with potential freedom around certain manufacturing processes or formulations not explicitly claimed.
4. Patent Term and Market Exclusivity
- The patent's term extends to 2032, assuming maintenance fees are paid.
- The patent's scope limits generic competition to formulations and methods outside the crystalline form claims.
5. Litigation and Licensing
No major litigation or licensing deals have publicly emerged. The patent's strength derives from its specific polymorph claims and process protections.
Comparison with Prior Art
- Crystalline forms of active ingredients are common in the pharmaceutical industry for stability and bioavailability improvements.
- Prior art includes amorphous forms and other crystalline polymorphs. The novelty lies in the specific crystalline structure with unique X-ray diffraction features, which are not disclosed in earlier patents or publications.
- The patent cited prior art but distinguished itself through the unique crystalline structure characterized by its diffraction pattern and stability profile.
Implications for Industry and R&D
- The patent provides enforceable exclusivity over crystalline forms, incentivizing innovations in polymorph development.
- Companies developing alternative polymorphs or amorphous formulations could design around this patent by avoiding the specific crystalline forms claimed.
- The process claims limit competitors' ability to manufacture using the disclosed methods, but alternative formulations might circumvent the patent.
Key Takeaways
- US Patent 8,840,916 claims a specific crystalline polymorph of a well-defined API, focusing on stability, manufacturability, and bioavailability.
- The scope includes composition, preparation methods, and therapeutic use.
- The patent landscape is well-established with international counterparts, limiting competitors’ freedom to operate around crystalline forms.
- Strategic development of alternative forms or methods could enable patenting of new compositions or processes, bypassing this patent.
- Market exclusivity is projected until 2032, provided maintenance fees continue.
FAQs
1. What specific crystalline features does US Patent 8,840,916 claim?
It claims a crystalline form with X-ray diffraction peaks at defined angles, indicating a unique polymorph not disclosed in prior art.
2. How does this patent impact generic drug development?
It restricts the production of generics using the crystalline form described but permits formulations or methods outside its claims, enabling potential design-arounds.
3. Are there known challenges or risks associated with patent infringement?
Potential challenges include invalidity claims based on prior art or non-infringement arguments if competitors develop alternative crystalline forms not covered by the patent.
4. Can a company develop a different polymorph and avoid infringement?
Yes, if the alternative crystalline form does not infringe on the specific diffraction pattern claims, it's possible to develop a non-infringing polymorph.
5. What is the international patent protection status for this compound?
Applications covering the same crystalline forms and processes have been filed in Europe, Japan, Canada, and other jurisdictions, providing broad protection.
References
[1] U.S. Patent 8,840,916.
[2] Patent family documents: EP, JP, CA filings.
[3] Market and patent landscape reports.
